-
Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself
Monday, November 7, 2016 - 11:19am | 300Read More...Piper Jaffray’s Joshua Schimmer believes there are several underappreciated risks ahead for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and would prefer greater visibility into some of the “moving parts” in the story. Schimmer downgraded the rating on the company from...
-
Could Regenxbio Shares Have 320% Upside?
Thursday, July 7, 2016 - 8:50am | 378Read More...Shares of Regenxbio Inc (NASDAQ: RGNX) could have 320 percent upside, according to Piper Jaffray, which has a price target of $33 on the stock. The $33 target price represents a potential upside of 320 percent from Wednesday's close of $7.86. "Regenxbio is a leader in the AAV gene therapy world and...
-
The Plot Thickens At Amgen; Piper Still Overweight
Wednesday, March 16, 2016 - 3:25pm | 376Read More...Piper Jaffray said the Street is underestimating the implications of the lawsuit of Amgen, Inc. (NASDAQ: AMGN) against Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (ADR) (NYSE: SNY) over its cholesterol-lowering drug Repatha. The District Court ruled in favor of Amgen...
-
Chimerix: Piper's 'Post-Blow-Up' Play
Tuesday, January 19, 2016 - 11:26am | 236Read More...Piper Jaffray issued a company note on Chimerix Inc (NASDAQ: CMRX) after a disappointing clinical trial, calling the company a "post-blow-up opportunity." Piper Jaffray rates Chimerix as Overweight and increased their price target from $11 to $18. Analysts Joshua Schimmer, Steven...
-
Piper Jaffray: Valeant's Business Could Be Broken Up In 2016
Friday, December 18, 2015 - 3:54pm | 861Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have lost around 55 percent since peaking at $264 back in August. Joshua Schimmer of Piper Jaffray suggested that Valeant could break up its corporate structure in 2016. The analyst suggested that many large investors might begin thinking the...
-
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
Friday, December 18, 2015 - 12:18pm | 441Read More...Shares of Akorn, Inc. (NASDAQ: AKRX) are lower by nearly 3 percent since the start of 2015. Despite the stock's $4 billion-plus valuation, Joshua Schimmer of Piper Jaffray suggested that it is "hard to rule out a delisting." The analyst cited uncertainty over the company...
-
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Friday, December 18, 2015 - 11:52am | 1283Read More...Joshua Schimmer of Piper Jaffray commented in a note that he is "eager to hit the reset button" within the biopharma sector. Schimmer presented a list of potential outcomes and events in 2016 which represent contrarian views or ones that investors "aren't even...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
-
5 Biotechs That Can Win From Ophthalmology Innovation
Monday, November 16, 2015 - 2:21pm | 628Read More...Joshua Schimmer, MD of Piper Jaffray attended the Ophthalmology Innovation Summit (OIS) and was "impressed" with the improving basic science and understanding of the eye structure. Schimmer added that ophthalmology offers investors "many compelling investment opportunities." Schimmer named five...
-
Calls Of Note: The Research Moving Stocks Today
Thursday, August 6, 2015 - 12:03pm | 907Read More...The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." FBR: Upgrading Sprint David Dixon of FBR & Co. upgraded shares of Sprint Corp (NYSE: S) to Outperform from Market Perform with...
-
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Wednesday, July 22, 2015 - 11:29am | 478Read More...In a report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Biogen Inc (NASDAQ: BIIB) to Neutral from Buy with a price target lowered to $410 from a previous $485 following the company's results for the 6mg Aducanumab arm in its P2 study for Alzheimer's....
-
Piper Jaffray Dishes On MannKind's Afrezza Data
Monday, May 11, 2015 - 11:52am | 601Read More...MannKind Corporation (NASDAQ: MNKD) reported first quarter 2015 results on May 7, revealing underwhelming sales and a mediocre Afrezza launch. Shares of MannKind last closed at $4.02, just above the 52-week low of $3.52. Some analysts are beginning to doubt if the company can make a comeback....
-
Biogen Or Bluebird: Which Will Lead In SCD?
Thursday, April 30, 2015 - 12:42pm | 428Read More...On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease, or SCD. The hereditary blood disorder is recognized by abnormal hemoglobin in the blood. Schimmer believes that to cure SCD with gene therapy, only...
-
Piper Jaffray Names Chimerix Inc Top Ebola Play
Thursday, October 2, 2014 - 11:11am | 133Read More...On Thursday, Piper Jaffray analysts raised the price target on shares of Chimerix Inc (NASDAQ: CMRX) to $37 from $33 and maintained an Overweight rating. In light of the current Ebola concerns, Piper Jaffray analysts believe that Chimerix is the top Ebola play. Joshua Schimmer finds that...
-
Piper Jaffray Not Convinced MannKind's Afreeza Will Be Commercial Success
Wednesday, April 2, 2014 - 2:42pm | 205Read More...On Wednesday, Piper Jaffray raised the price target for MannKind (NASDAQ: MNKD) from $1.50 to $2 and reiterated an Underweight rating following the FDA Advisory Committee recommended the approval of Afrezza. Analyst Joshua Schimmer believes the FDA will need added time to negotiate a “complex...
